These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 16799165)

  • 1. Case finding for hepatitis C in primary care: a cost utility analysis.
    Thompson Coon J; Castelnuovo E; Pitt M; Cramp M; Siebert U; Stein K
    Fam Pract; 2006 Aug; 23(4):393-406. PubMed ID: 16799165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
    Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
    Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What is the cost utility of screening for hepatitis C virus (HCV) in intravenous drug users?
    Leal P; Stein K; Rosenberg W
    J Med Screen; 1999; 6(3):124-31. PubMed ID: 10572842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for Hepatitis C in injecting drug users: a cost utility analysis.
    Stein K; Dalziel K; Walker A; Jenkins B; Round A; Royle P
    J Public Health (Oxf); 2004 Mar; 26(1):61-71. PubMed ID: 15044577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What is the cost-effectiveness of hepatitis C treatment for injecting drug users on methadone maintenance in New Zealand?
    Sheerin IG; Green FT; Sellman JD
    Drug Alcohol Rev; 2004 Sep; 23(3):261-72. PubMed ID: 15370005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of the HepCATT intervention in specialist drug clinics to improve case-finding and engagement with HCV treatment for people who inject drugs in England.
    Ward Z; Reynolds R; Campbell L; Martin NK; Harrison G; Irving W; Hickman M; Vickerman P
    Addiction; 2020 Aug; 115(8):1509-1521. PubMed ID: 31984606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal control of hepatitis C antiviral treatment programme delivery for prevention amongst a population of injecting drug users.
    Martin NK; Pitcher AB; Vickerman P; Vassall A; Hickman M
    PLoS One; 2011; 6(8):e22309. PubMed ID: 21853030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.
    Hornberger J; Torriani FJ; Dieterich DT; Bräu N; Sulkowski MS; Torres MR; Green J; Patel K
    J Clin Virol; 2006 Aug; 36(4):283-91. PubMed ID: 16765638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HCV screening to enable early treatment of hepatitis C: a mathematical model to analyse costs and outcomes in two populations.
    Tramarin A; Gennaro N; Compostella FA; Gallo C; Wendelaar Bonga LJ; Postma MJ
    Curr Pharm Des; 2008; 14(17):1655-60. PubMed ID: 18673188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating the cost-effectiveness of needle-syringe programs in Australia.
    Kwon JA; Anderson J; Kerr CC; Thein HH; Zhang L; Iversen J; Dore GJ; Kaldor JM; Law MG; Maher L; Wilson DP
    AIDS; 2012 Nov; 26(17):2201-10. PubMed ID: 22914579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and cost-effectiveness of nationwide campaigns for awareness and case finding of hepatitis C targeted at people who inject drugs and the general population in the Netherlands.
    Helsper CW; Janssen MP; van Essen GA; Croes EA; van der Veen C; de Wit AG; de Wit NJ
    Int J Drug Policy; 2017 Sep; 47():117-125. PubMed ID: 28826994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment costs of hepatitis C infection among injection drug users in Canada, 2006-2026.
    Werb D; Wood E; Kerr T; Hershfield N; Palmer RW; Remis RS
    Int J Drug Policy; 2011 Jan; 22(1):70-6. PubMed ID: 21051212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
    Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
    JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing hepatitis C virus screening in people who inject drugs in Switzerland using rapid antibody saliva and dried blood spot testing: A cost-effectiveness analysis.
    Girardin F; Hearmon N; Negro F; Eddowes L; Bruggmann P; Castro E
    J Viral Hepat; 2019 Feb; 26(2):236-245. PubMed ID: 30338887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for hepatitis C in genito-urinary medicine clinics: a cost utility analysis.
    Stein K; Dalziel K; Walker A; Jenkins B; Round A; Royle P
    J Hepatol; 2003 Nov; 39(5):814-25. PubMed ID: 14568266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland.
    Hutchinson SJ; Bird SM; Goldberg DJ
    Hepatology; 2005 Sep; 42(3):711-23. PubMed ID: 16116637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The costs of not treating hepatitis C virus infection in injecting drug users in New Zealand.
    Sheerin IG; Green FT; Sellman JD
    Drug Alcohol Rev; 2003 Jun; 22(2):159-67. PubMed ID: 12850902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic model of a birth cohort screening program for hepatitis C virus.
    McGarry LJ; Pawar VS; Panchmatia HR; Rubin JL; Davis GL; Younossi ZM; Capretta JC; O'Grady MJ; Weinstein MC
    Hepatology; 2012 May; 55(5):1344-55. PubMed ID: 22135116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
    Sullivan SD; Jensen DM; Bernstein DE; Hassanein TI; Foster GR; Lee SS; Cheinquer H; Craxi A; Cooksley G; Klaskala W; Pettit K; Patel KK; Green J
    Am J Gastroenterol; 2004 Aug; 99(8):1490-6. PubMed ID: 15307866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System.
    Yeh WS; Armstrong EP; Skrepnek GH; Malone DC
    Pharmacotherapy; 2007 Jun; 27(6):813-24. PubMed ID: 17542764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.